MK-8262   Click here for help

GtoPdb Ligand ID: 11729

Synonyms: compound 87 ]PMID: 34375108] | MK8262
Compound class: Synthetic organic
Comment: MK-8262 is a small molecule that inhibits cholesterylester transfer protein (CETP; P11597) [2]. It was developed as a best-in-class back-up clinical candidate to anacetrapib, but like anacetrapib its development was discontinued. CETP was considered as a target for prevention of dyslipidemia and reducing cardiovascular mortality, with CETP inhibitors proposed as a direct route to raise HDL.
Clinical trial results for a number of CETP inhibitors have failed to show clinical benefit. Failed candidates in addition to this one, include evacetrapib, anacetrapib, torcetrapib, and dalcetrapib [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 88.96
Molecular weight 724.16
XLogP 10.08
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COc1ncc(cc1c1ccc(cc1[C@@H]1CC[C@@H]2N1C(=O)O[C@@H]2c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)c1ccc(cc1C)C(=O)O
Isomeric SMILES FC(c1cc(cc(c1)C(F)(F)F)[C@@H]1[C@H]2N(C(=O)O1)[C@@H](CC2)c1c(ccc(c1)C(F)(F)F)c1cc(cnc1OC)c1c(cc(C(=O)O)cc1)C)(F)F
InChI InChI=1S/C35H25F9N2O5/c1-16-9-17(31(47)48)3-5-23(16)19-12-26(30(50-2)45-15-19)24-6-4-20(33(36,37)38)14-25(24)27-7-8-28-29(51-32(49)46(27)28)18-10-21(34(39,40)41)13-22(11-18)35(42,43)44/h3-6,9-15,27-29H,7-8H2,1-2H3,(H,47,48)/t27-,28-,29+/m0/s1
InChI Key VYZPBLVSILOWMJ-YTCPBCGMSA-N
No information available.
Summary of Clinical Use Click here for help
MK-8262 was evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in a randomized, placebo-controlled, double-blind phase 1 clinical trial in healthy volunteers [2]. Its development was discontinued for strategic reasons, and was not related to any nonclinical or clinical safety issues.